ライフサイエンスコーパス: protection against

1 concentration conferred by 1 is 3.2 muM with protection against 200 muM neomycin approaching 100%.

2 individual traits, in combination providing protection against a broad spectrum of herbivores.

3 f these cells into mice confers long lasting protection against a high dose of BoNT/A.

4 dose of H3N8 LACIV showed immunogenicity and protection against a homologous challenge that was bette

5 izing antibodies (VNAs), resulting in better protection against a lethal challenge than that seen wit

6 al and cellular responses, and afforded 100% protection against a lethal intracerebral dose of ZIKV (

7 alum adjuvant, and they resulted in enhanced protection against a low-dose intravaginal challenge wit

8 known as Rv21, able to provide 100% sterile protection against a stringent sporozoite challenge in r

9 ls, with the potential to contribute to herd protection against a subset of strains.

10 ay of a prokaryotic cell which maximizes its protection against a viral attack.

11 s-neutralizing antibody (VNA) production and protection against a virulent RABV challenge.

12 the Solanaceae family and are implicated in protection against abiotic and biotic stress.

13 low-dose challenge study, we observe robust protection against acquisition of infection by both Ad A

14 Glial cells offer protection against AD by engulfing extracellular Abeta p

15 Preservation of contractile function and protection against adverse changes in ventricular archit

16 tent of the vaccines, significantly enhanced protection against aerosolized M. tuberculosis (P < 0.01

17 As such, they provide protection against age-associated changes and a plethora

18 ce of endogenous Treg, IVIg failed to confer protection against AHR and airway inflammation.

19 or a lower ejection fraction, pLVAD support protection against AKI persisted (adjusted odds ratio, 0

20 Lifestyle (PARSIFAL) study (n = 299) and the Protection Against Allergy Study in Rural Environments (

21 The Protection Against Allergy Study in Rural Environments (

22 Allergiestudie (MAS) and 766 children of the Protection against allergy: Study in Rural Environments

23 The improved protection against amalgam saturation allows Hg disc-wel

24 cGAS-independent mechanism of STING-mediated protection against an intracellular bacterial infection.

25 llenge, we found that EPIT induced sustained protection against anaphylaxis.

26 CD8(+) T cells may play a dual role in protection against and pathogenesis of flaviviruses, inc

27 spase-2, -9 and -3/7 activities and provided protection against apoptosis in human melanoma cells, su

28 tionable CRPC therapeutic target through its protection against AR-induced redox stress.

29 At 4.5 years, protection against asthma by farm-milk exposure was part

30 ing YscU variant P264A conferred significant protection against autoproteolysis.

31 he contribution of different IgG isotypes to protection against bacteria such as S.

32 sing VHHs can provide prolonged prophylactic protection against bacterial toxins without inducing inh

33 aryotic adaptive immune systems that provide protection against bacteriophage (phage) and other paras

34 They also provide novel strategies for crop protection against biotrophs without compromising resist

35 Classical vaccines that afford protection against bluetongue virus, the etiological age

36 fic anticapsular antibody is associated with protection against both early-onset and late-onset group

37 RNA therapeutic that provides broad-spectrum protection against both MARV and RAVV.

38 ent with known anticarcinogenic effects, but protection against breast cancer has not been establishe

39 nd long-term treatment with ACEis may confer protection against breast cancer.

40 that STING but not cGAS is critical for host protection against Brucella infection in macrophages and

41 ntified a minimal set of cell types for skin protection against C. albicans invasion.

42 tigated host genetic factors associated with protection against CD4(+)T-cell loss in HIV-1-controller

43 distinct bacterial taxa was correlated with protection against CDI: Bacteroidetes, Lachnospiraceae,

44 CP is a new and powerful mediator of cardiac protection against cell death in vivo, as evidenced by a

45 ved in the control of cell proliferation and protection against cell death.

46 Vaccination with PIV5-N1 NA provided cross-protection against challenge with a heterosubtypic (H3N2

47 her infection with TC-PC177 can induce cross-protection against challenge with a highly virulent PEDV

48 unization with anti-OmpA MAbs did not confer protection against challenge with AB307-0294, the encaps

49 ific virulence-associated genes induce solid protection against challenge with parental viruses.

50 cal signs in pigs and induced high levels of protection against challenge with the parental virulent

51 fUIS3 can also provide partial cross-species protection against challenge with wild-type P. berghei p

52 e malaria vaccine has demonstrated long-term protection against CHMI using Pf parasites heterologous

53 INTERPRETATION: Two kOCV doses provide protection against cholera for at least 3 years.

54 Contemporary understanding of immune protection against cholera, which results from local int

55 ting MNV-specific Trm cells provided partial protection against chronic infection but largely ceased

56 hanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.

57 4788863 in SLC16A5, that was associated with protection against cisplatin-induced ototoxic effects in

58 ne signatures predictive of individual-level protection against clinical disease.

59 nfants and that its presence correlates with protection against clinical malaria during infancy.

60 Mucosal immunity is considered important for protection against Clostridium difficile infection (CDI)

61 FDA-approved EP4 agonist, conferred similar protection against CML.

62 umoral immune responses that are involved in protection against congenital HCMV infection.IMPORTANCE

63 (dHLD or HLD/ETO) did not provide additional protection against contamination.

64 ite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (C

65 an be achieved for long-term (i.e., 28 days) protection against corneal aberration and retinal injury

66 to masks, N95 respirators conferred superior protection against CRI (RR = 0.47; 95% CI: 0.36-0.62) an

67 ncestral, susceptible allele provides strong protection against DCV; indicating that this mutation ac

68 lues >-0.5 (RR: 0.579; 95% CI: 0.463, 0.724).Protection against delivering an SGA neonate offered by

69 of a neutralizing antibody to correlate with protection against dengue virus have highlighted the nee

70 accine approaches that can provide long-term protection against dengue virus infection is needed.

71 r persisting vectors for achieving long-term protection against dengue virus infection.IMPORTANCE Con

72 o the identification of robust correlates of protection against dengue virus.

73 not appear to have a role in explaining the protection against depression.

74 production, and insulin secretion as well as protection against diabetes.

75 Where symbionts provided protection against different natural enemies, no alterat

76 nasal treatment of mice with DK128 conferred protection against different subtypes of influenza virus

77 the absence of a vaccine that elicits broad protection against different virus strains.

78 e-PEG copolymer, enabling up to a 1,000-fold protection against digestion by serum nucleases.

79 n of host-associated microbiota might confer protection against diseases later in life.Early-life mic

80 bodies alone are sufficient to provide broad protection against divergent virus strains in vivo.

81 conserved GyrI-like proteins confer cellular protection against diverse xenobiotics via not only bind

82 ls vaccinated with the cVLP showed 20% cross-protection against drifted (Philippines) and 60% protect

83 TO and standard curcumin treatments provided protection against DSS-induced inflammation.

84 ections alone reversed the fasting-dependent protection against DXR in mice, indicating that elevated

85 esis of carotenoids was also associated with protection against EAC.

86 ssessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases am

87 presented demonstrate that EBOTAb conferred protection against EBOV when given post-exposure and sho

88 ibodies are essential for rVSV-EBOV mediated protection against EBOV; however, the mechanisms by whic

89 and B cell-mediated immunity, especially for protection against EBV and humoral immunity.

90 influenza virus vaccine efficacy and provide protection against emerging influenza viruses.

91 of CaneCPIs in dental products might confer protection against enamel erosion.

92 nt flu vaccines have failed to provide cross-protection against evolving viruses in the field.

93 lating GR activation and providing enzymatic protection against excessive GR activation in obesity.

94 us to probe the effects of NAD(+) and NR in protection against excitotoxicity.

95 ther the TSCA revisions offer greater public protection against existing and new chemicals.

96 is the main driver of L lactis G121-mediated protection against experimentally induced allergy and re

97 his system provides an intrinsic topological protection against external perturbations.

98 Protection against fatty liver is partially recapitulate

99 nce interval [CI] = .30-.73; P = .0008) with protection against febrile malaria.

100 ted erythrocytes without conferring enhanced protection against febrile malaria.

101 matic patients (n = 63) CNTO3157 provided no protection against FEV1 decrease (least squares mean: CN

102 of WT bone-marrow-derived Mvarphi conferred protection against fibrosis in these mice.

103 Antibodies are pivotal in providing protection against FMDV infection.

104 s with carboxyl-amine functionalities offers protection against formation of an insulating polydopami

105 nctionally impaired and they fail to provide protection against Francisella novicida upon adoptive tr

106 pe I IFNs were also previously implicated in protection against fungal infection, but their roles in

107 confer different phenotypes on their hosts (protection against fungal pathogens vs. parasitoid wasps

108 the effector populations involved in humoral protection against genital chlamydia infection is crucia

109 ide genetic evidence for a role for IFI16 in protection against genital herpes.

110 D treatment or Cav-3 knockdown abolished the protection against H/R-induced myocytes injury by AS-1.

111 ning high anthocyanins provided the greatest protection against H2O2.

112 ted cross-reactive immunity and heterologous protection against H3N2 CIV.

113 onses, involved in providing long-term cross-protection against H3N2 influenza virus when compared to

114 ivo and ex vivo The LACIV was able to induce protection against H3N8 CIV challenge with a single intr

115 gher levels of IGF-1 appeared to confer some protection against hearing impairment in some older adul

116 Protection against herpes zoster (HZ) induced by the liv

117 more conserved fusion protein contribute to protection against heterologous CDV strains.IMPORTANCE R

118 nst lethal homologous challenge and complete protection against heterologous challenge.

119 iC MNP-boosted group also possessed enhanced protection against high lethal dose challenges against h

120 Melanin afforded protection against high-dose (1.5 kGy) deuterons for bot

121 Furthermore, the HLA-B*14-associated protection against HIV disease progression is significan

122 the RV144 vaccine trial elicited significant protection against HIV-1 acquisition, but the efficacy a

123 d to boost the efficacy and immune memory of protection against HIV-1 in the clinical trial.

124 of these complex immunological mechanisms of protection against HIV-1 will accelerate the development

125 V-specific CD4(+) T cell responses to immune protection against HIV-1, particularly in clade C infect

126 ovide evidence that IFNbeta confers neuronal protection against HIVgp120 toxicity.

127 ection against drifted (Philippines) and 60% protection against homologous (Aichi) H3N2 viruses.

128 tibody and T cell responses, which conferred protection against homologous and heterologous influenza

129 Collectively, these data suggest durable protection against homologous and heterologous Pf parasi

130 evels of nAb, H7 vaccines conferred complete protection against homologous virus challenge in mice, a

131 lusive to mycobacteria, with likely roles in protection against host defenses.

132 d induced immune memory, suggesting possible protection against HPV vaccine types after a single dose

133 genous type I IFN signalling offered limited protection against HRV.

134 umoral immunity is an essential correlate of protection against HSV-1 pathogenesis and ocular patholo

135 designing effective and enduring therapeutic protection against human or avian influenza viruses.

136 Vaccine-mediated protection against human pathogens can be achieved throu

137 ceed in raising safe, effective, and durable protection against human Zika virus infections or syndro

138 Increased protection against hydrogen exchange with solvent is mon

139 Sc) is characterized by substantially higher protection against hydrogen/deuterium exchange in the C-

140 cyclin-dependent kinase Pho85/CDK5 provides protection against hyperosmotic stress and acts before l

141 Elucidating the mechanisms involved in CPC protection against hypoxic stress is essential to maximi

142 primary and secondary analyses, HZV provided protection against HZ across all ages, but effectiveness

143 s play an important role in vaccine-mediated protection against infection but the underlying mechanis

144 enetically induced barrier ablation provides protection against infection by activating the immune re

145 Protection against infection increased with the order of

146 rolled inflammatory response is required for protection against infection, but persistent inflammatio

147 in SPH2015 from Brazil resulted in continued protection against infection, no viral shedding, and boo

148 lls (TRM) have been shown to afford superior protection against infection, particularly against patho

149 antibody responses in vaginal secretions and protection against infection.

150 are required for immune cell development and protection against infections and are also associated wi

151 Protection against infections can be achieved through va

152 d at altering natural Ab levels critical for protection against infectious disease, autoimmunity, all

153 These distinct processes underlie protection against infectious diseases after natural inf

154 Natural killer (NK) cells provide protection against infectious pathogens and cancer.

155 ory cell-death pathway and was important for protection against inflammation induced by ROS or ROS-ge

156 ersal influenza vaccines is to provide broad protection against influenza A and B viruses.

157 lder adults, we found that TIV provided good protection against influenza hospitalization in older ad

158 city (ADCC) may be an important component of protection against influenza infection.

159 these viral vectors can mediate more potent protection against influenza virus infection in animal m

160 Antibody responses are essential for protection against influenza virus infection.

161 have been used successfully to induce broad protection against influenza viruses in humans, and our

162 provide potent prophylactic and therapeutic protection against influenza, even after extensive repea

163 ti-cancer capacity, it can offer significant protection against inhibitors of PLK1, but the events un

164 ly replace intestinal bacteria by conferring protection against injury to mucosal tissues and positiv

165 crophages conferred control mice conspicuous protection against insult.

166 buted to understand the role of IFN-gamma in protection against intracellular pathogens.

167 bacterial killing in macrophages and boosted protection against intravenous bacterial challenge.

168 n prokaryotic Agos hint at their role in the protection against invading DNA(2,3).

169 st group B Streptococcus (GBS) might provide protection against invasive GBS disease in infants.

170 eed for a booster dose to sustain individual protection against invasive meningococcal disease.

171 with the parent peptide) to induce complete protection against invasive streptococcal disease.

172 leads to reduced atherosclerosis and affords protection against ischemia/reperfusion injury of the ce

173 on with a subunit vaccine (H56) induced poor protection against it.

174 emonstrate how light can enhance topological protection against lattice perturbations.

175 that pre-exposure to sand fly saliva confers protection against leishmaniasis.

176 only does vaccination provide high levels of protection against lethal aerosol challenge with B. mall

177 n immunization the gamma134.5 mutant induces protection against lethal challenge by the wild type vir

178 tural infection and could provide additional protection against lethal DENV infection.

179 eting Pseudomonas aeruginosa proteins confer protection against lethal pneumonia in mice.

180 fore endotoxin, scFv/TM provided more potent protection against liver injury and release of pathologi

181 ntion due to its varied applications such as protection against loss of bone mass, chronic diseases,

182 the liver expresses IFN-gamma and can confer protection against M. avium infection in immunocompromis

183 found OP of merozoites to be associated with protection against malaria and further shows IgG3 and GL

184 A high level (more than 90%) of protection against malaria in humans has previously been

185 Although CD8(+) T cells provide protection against many viral infections, their role in

186 al studies that reported estimates of direct protection against medically attended confirmed cholera

187 SOCS1-transduced viable tumor cells rendered protection against melanoma in a syngeneic model, with d

188 for MC1R palmitoylation in pigmentation and protection against melanoma.

189 suggest that vaccination may provide better protection against meningococcal disease in patients tre

190 te alcohol intake improves human health with protection against metabolic syndromes, including type 2

191 ring the bone marrow confers some measure of protection against metastasis, challenging present views

192 ne response during macrophage activation and protection against microbial infections.

193 for purposes of simplicity, cost, and broad protection against multiple National Institute of Allerg

194 K1/2-dependent upregulation of MCU conferred protection against mutant LRRK2-elicited dendrite shorte

195 les in host ecology and evolution, including protection against natural enemies.

196 cal applications, from biofilm disruption to protection against neurodegeneration and tumor preventio

197 pulation of peripheral CD4 T cells conferred protection against new tumors and was significantly expa

198 was to address 1) whether exercise provides protection against new-onset depression and anxiety and

199 cluding cellular immunity, which may provide protection against newly emerging strains.

200 on pattern resulting in different degrees of protection against nuclease activity.

201 ated knockdown of FcRn in the cornea impeded protection against ocular HSV-1 challenge in vaccinated

202 The microcapsules (13-42mum) promoted protection against oil oxidation (induction time of 54.9

203 neonates, our demonstration of the selective protection against OIR, effective therapeutic window, ad

204 Serological protection against one FMDV serotype does not confer int

205 a low dose of endotoxin confers unparalleled protection against otherwise lethal models of sepsis.

206 ensitive functional food ingredients and its protection against oxidation.

207 n, leading to cell-cycle inhibition and cell protection against oxidative challenge.

208 id peroxidation, indicating a role of TAG in protection against oxidative damage.

209 d BCL2L1 (BCL2-like 1) which are involved in protection against oxidative stress and apoptosis, respe

210 utilization, improved muscle energetics, and protection against oxidative stress.

211 K210/247 antigen can elicit high level cross-protection against parasites expressing either CSP allel

212 at Cu is a host effector that is involved in protection against pathogen colonization of the urinary

213 te immune homeostasis, immune responses, and protection against pathogen colonization.

214 vaccines is attractive for the immunological protection against pathogen entry directly at the site o

215 UF1, to germfree mice conferred protection against pathogen infection and correlated wit

216 terns (PAMPs) to elicit defenses and provide protection against pathogens.

217 ong-acting beta2 -adrenergic agonists confer protection against pathologic airway changes is warrante

218 ed PD-L2(-/-) mice with selectively enhanced protection against PC-expressing nontypeable Haemophilus

219 In photosynthetic organisms, protection against photooxidative stress due to singlet

220 cental, and fetal tissues, which resulted in protection against placental damage and fetal demise.

221 ia vaccine candidate and confers significant protection against Plasmodium falciparum infection in hu

222 nase (G6PD) deficiency is believed to confer protection against Plasmodium falciparum malaria, but th

223 Protection against poliovirus remained elevated 6 and 11

224 We suggest that protection against predators conferred by their high tox

225 ough some of the forms only provide moderate protection against predators.

226 Thus, HCA2 plays a critical role in host protection against pro-inflammatory insults.

227 ls conferred interleukin (IL)-10-independent protection against PTL.

228 onses induced by rRABV-mBAFF confer improved protection against RABV in a PEP model.

229 effector for NF-E2-related factor 2-mediated protection against radiation-induced skin injury by inhi

230 metalloproteins for oxidative metabolism and protection against reactive oxygen species.

231 eptibility to cerebral malaria and conferred protection against recombinant Listeria monocytogenes in

232 cells (TCM), locally within TG, and improved protection against recurrent herpesvirus infection and d

233 (+) TEM and CD8(+) TRM cells associated with protection against recurrent ocular herpes.

234 s in healthy adults as a mechanism governing protection against reinfection by HAstV.

235 ment of CMV disease did not confer long-term protection against relapse, although it did delay relaps

236 of restraint stress, mediated by C1 neurons: protection against renal ischemia-reperfusion injury.

237 responses that were associated with enhanced protection against repeated low-dose, intravaginal chall

238 , HVEM-deficient recipients failed to afford protection against respiratory reinfection with influenz

239 Choroidal gammadelta T cells in protection against retinal pigment epithelium and retina

240 RIG-I-like receptors (RLRs) are critical for protection against RNA virus infection, and their activi

241 ort studies to understand naturally acquired protection against rotavirus infection and RVGE.

242 obulin G titers were associated with partial protection against rotavirus infection.

243 ng RSV fusion (F) protein to confer bivalent protection against RSV and HPIV3.

244 nt RSV-neutralizing antibodies and providing protection against RSV challenge.

245 replication, immunogenicity, and efficacy of protection against RSV challenge.

246 milar to those of wild-type RSV and provided protection against RSV challenge.

247 ith greater pre-F site O binding and greater protection against RSV challenge.

248 rived RSV-specific antibodies play a role in protection against RSV infection in early life, but data

249 PIV5/F provided nearly complete protection against RSV infection in the upper and lower

250 naling and microbiota in H polygyrus-induced protection against RSV.

251 Dissimilar estimates of protection against RVGE may be due in part to age-relate

252 We reassessed protection against RVGE, decomposing the incidence rate

253 the antimicrobial function of macrophages in protection against S. aureus infection.

254 nization resulted in 83% or 50% heterologous protection against Salmonella Choleraesuis challenge, re

255 ted during primary DENV infection can confer protection against secondary ZIKV infection in mice.

256 ns, indicating that antibody correlates with protection against sepsis but not nasal carriage.

257 sepsis, or whether hRetn influences helminth protection against sepsis, is unknown.

258 belonged to the most efficient compounds in protection against SIN-1 induced oxidation of dihydrorho

259 wo gene variants provide different levels of protection against sleeping sickness, but this comes wit

260 a high degree of sterile infection-blocking protection against sporozoite challenge in a stringent r

261 ed that platelets functionally contribute to protection against Staphylococcus aureus infection.

262 Serotype-specific protection against Streptococcus pneumoniae is an import

263 ee prior infections conferred 74% (P < .001) protection against subsequent infection in sites not usi

264 Multiple reinfections conferred some protection against subsequent infection.

265 (WT) GP/VSVDeltaG and did not provide cross protection against Sudan virus.

266 t be evaluated separately from correlates of protection against symptomatic disease.

267 e cells in mediating clinical immunity (i.e. protection against symptoms) to malaria remains unclear.

268 findings support the idea that physiological protection against synaptotoxic AbetaOs can be mediated

269 in tap water and thus confer enteric viruses protection against temperature and the classical disinfe

270 Helicobacter pylori confers protection against the anaphylaxis associated with ovalb

271 VCM), Gbeta5 deficiency provided substantial protection against the cytotoxic actions of chemotherape

272 cription factors play a salutary role in the protection against the diet-induced fatty liver disease.

273 er, CD8(+) T cell-depleted mice displayed no protection against the heterosubtypic virus challenge af

274 MPTP mouse model of PD conferred significant protection against the loss of tyrosine hydroxylase (TH)

275 Where symbionts provided protection against the same natural enemy, the level of

276 There is also evidence of herd protection against the vaccine-specific and cross-protec

277 und in amphibians, commensal bacteria confer protection against this pathogen.

278 The key challenge of how to provide optimal protection against thrombotic events without excessive i

279 encodes a transcription factor essential for protection against tissue injury, our data have revealed

280 s Abisco-100 and Matrix-M it elicits sterile protection against transgenic sporozoite challenge.

281 A2A adenosine receptor provided significant protection against tumor initiation and metastasis forma

282 ory states, long memory retention times, and protection against unavoidable noise.

283 Furthermore, significant protection against unrelated coinfecting viral pathogens

284 ne as a host response to UTI and its role in protection against UTI remain unresolved.

285 2 expression was required and sufficient for protection against V8 protease-mediated integrity damage

286 strong cross-strain as well as cross-subtype protection against various virus strains.

287 hydrogen sulfide-triggered mechanism in the protection against ventilator-induced lung injury involv

288 ndromic repeats (CRISPR)-Cas systems provide protection against viral and plasmid infection by captur

289 t not naive controls, yet it does not confer protection against viral challenge.

290 duction of innate immunity genes and confers protection against viral infection.

291 cultures with chIFN-kappa imparted cellular protections against viral infections both in vitro and e

292 haemolymph of infected flies, confer passive protection against virus challenge in naive animals.

293 fective H5N1 vaccine must ultimately provide protection against viruses from diverse clades.

294 ty epitope provided strong, T cell-dependent protection against viruses or tumors.

295 /-) parasite-induced immunity and subsequent protection against visceral leishmaniasis.

296 ment with 25HC reduced viremia and conferred protection against ZIKV in mice and rhesus macaques.

297 ased on the NS1 protein and (ii) single dose protection against ZIKV using an immunocompetent lethal

298 A substantial protection against ZIKV-infected and old noninfected mos

299 erol (25HC), was a critical mediator of host protection against ZIKV.

300 an blood cells are likely to be important in protection against zoonotic infection with FeLV.IMPORTAN